Q1 2026 · 13F-HR
Affinity Asset Advisors, LLCholdings as filed
Filed 2026-05-14 · accession 0001315863-26-000411
$1.94B
Reported value
105
Positions
2026-03-31
Period end
The Brief · Affinity Asset Advisors, LLC · Q1 2026
AI · grounded in 13F
Affinity Asset Advisors, LLC closed its position in XBI, reducing exposure by $182.9M. The fund established a new position in SPY worth $130.1M and added MRNA to the portfolio with a $40.6M investment. Other activity included closing positions in IBB and VTYXUSD, while increasing share counts in CNTA by 133.1%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78462F103 | SPY | STATE STR SPDR S&P 500 ETF T | $130.1M | 6.72% | 200,000 | PUT | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $108.2M | 5.59% | 1,284,926 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $97.4M | 5.03% | 1,675,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $86.6M | 4.47% | 5,350,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $78.5M | 4.05% | 480,000 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $77.6M | 4.01% | 2,800,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $64.5M | 3.33% | 1,279,134 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $55.6M | 2.87% | 1,400,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $54.8M | 2.83% | 170,000 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $52.1M | 2.69% | 940,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $47.7M | 2.47% | 1,350,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $46.2M | 2.38% | 700,483 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $45.1M | 2.33% | 405,000 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $42.2M | 2.18% | 1,400,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $41.7M | 2.15% | 362,764 | Common | SOLE |
| 60770K107 | MRNA | MODERNA INC | $40.6M | 2.10% | 800,000 | CALL | SOLE |
| 670703107 | NUVL | NUVALENT INC | $30.7M | 1.59% | 300,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $29.7M | 1.53% | 562,631 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $29.4M | 1.52% | 350,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $29.0M | 1.50% | 5,050,211 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $28.9M | 1.49% | 750,000 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $28.8M | 1.49% | 55,000 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $26.6M | 1.38% | 1,069,519 | Common | SOLE |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $26.2M | 1.35% | 1,011,890 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $24.5M | 1.27% | 499,673 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $23.9M | 1.23% | 2,000,172 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $23.6M | 1.22% | 10,636,318 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $23.0M | 1.19% | 586,904 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $21.7M | 1.12% | 95,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $20.3M | 1.05% | 750,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $20.0M | 1.03% | 1,340,840 | Common | SOLE |
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $18.2M | 0.94% | 300,000 | CALL | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $18.1M | 0.94% | 172,125 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $15.9M | 0.82% | 500,000 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $15.3M | 0.79% | 2,564,303 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $15.0M | 0.77% | 967,620 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $13.7M | 0.71% | 2,512,153 | Common | SOLE |
| 682143AK8 | OMER 9.5 06/15/29 | OMEROS CORP | $13.2M | 0.68% | 6,525,000 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $13.2M | 0.68% | 3,164,582 | Common | SOLE |
| G4444S107 | HLXC | HELIX ACQUISITION CORP III | $12.7M | 0.66% | 1,250,000 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $12.5M | 0.65% | 200,000 | Common | SOLE |
| 36322Q206 | DMRA | DAMORA THERAPEUTICS INC | $11.7M | 0.60% | 450,000 | Common | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $11.5M | 0.59% | 1,589,005 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $11.2M | 0.58% | 500,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $11.1M | 0.58% | 150,000 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $11.1M | 0.57% | 781,260 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC | $10.4M | 0.54% | 65,000 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $10.2M | 0.52% | 1,401,727 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $10.1M | 0.52% | 250,000 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $9.9M | 0.51% | 257,512 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $9.7M | 0.50% | 100,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $9.7M | 0.50% | 100,000 | PUT | SOLE |
| 45256X103 | IBRX | IMMUNITYBIO INC | $9.6M | 0.50% | 1,250,000 | PUT | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $9.0M | 0.46% | 639,956 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $8.9M | 0.46% | 300,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $8.8M | 0.45% | 275,000 | Common | SOLE |
| 19240QAA0 | COGT 1.625 11/15/31 | COGENT BIOSCIENCES INC | $8.6M | 0.44% | 7,000,000 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $8.0M | 0.41% | 706,904 | Common | SOLE |
| 15102KAA8 | CELC 2.75 08/01/31 | CELCUITY INC | $7.3M | 0.38% | 3,000,000 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $7.1M | 0.37% | 150,000 | Common | SOLE |
| 85220G109 | SGP | SPYGLASS PHARMA INC | $6.5M | 0.33% | 250,000 | Common | SOLE |
| 670100205 | NVO | NOVO-NORDISK A S | $6.4M | 0.33% | 175,000 | CALL | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $6.1M | 0.32% | 1,108,483 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $5.9M | 0.30% | 3,107,200 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $5.7M | 0.29% | 100,000 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $5.1M | 0.26% | 912,397 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $4.9M | 0.25% | 245,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $4.9M | 0.25% | 300,000 | CALL | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $4.9M | 0.25% | 250,000 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $4.8M | 0.25% | 700,000 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $4.7M | 0.24% | 1,547,641 | Common | SOLE |
| 786700104 | SGMT | SAGIMET BIOSCIENCES INC | $4.5M | 0.23% | 868,020 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $4.5M | 0.23% | 150,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $4.5M | 0.23% | 1,000,000 | Common | SOLE |
| 922967104 | MANE | VERADERMICS INC | $4.4M | 0.23% | 70,000 | Common | SOLE |
| 370920100 | GENB | GENERATE BIOMEDICINES INC | $4.4M | 0.23% | 350,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $4.2M | 0.22% | 50,000 | CALL | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $4.2M | 0.21% | 610,370 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $4.1M | 0.21% | 60,000 | CALL | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $4.0M | 0.21% | 175,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $4.0M | 0.21% | 400,000 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $4.0M | 0.21% | 2,454,278 | Common | SOLE |
| 92511W207 | VRCA | VERRICA PHARMACEUTICALS INC | $3.7M | 0.19% | 707,338 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $3.4M | 0.18% | 30,000 | CALL | SOLE |
| 74019P207 | DTIL | PRECISION BIOSCIENCES INC | $3.3M | 0.17% | 597,946 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $2.8M | 0.14% | 500,000 | Common | SOLE |
| M8694L137 | SLGL | SOL-GEL TECHNOLOGIES LTD | $2.8M | 0.14% | 35,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $2.7M | 0.14% | 75,000 | Common | SOLE |
| G6717R120 | OACCU | OAKTREE ACQUISITION CORP III | $2.7M | 0.14% | 250,000 | Common | SOLE |
| 65343E207 | NXTC | NEXTCURE INC | $2.6M | 0.13% | 241,826 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $2.5M | 0.13% | 100,000 | Common | SOLE |
| 29446K106 | EQ | EQUILLIUM INC | $2.5M | 0.13% | 1,226,310 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $2.2M | 0.11% | 575,000 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $2.0M | 0.10% | 50,000 | Common | SOLE |
| 68572M106 | OBIO | ORCHESTRA BIOMED HLDGS INC | $1.7M | 0.09% | 402,550 | Common | SOLE |
| 49372L209 | 2KZ0 | KEZAR LIFE SCIENCES INC | $1.7M | 0.09% | 229,076 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $1.4M | 0.07% | 500,000 | Common | SOLE |
| 00704R109 | ANL | ADLAI NORTYE LTD | $1.1M | 0.06% | 164,748 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $1.1M | 0.06% | 500,000 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $997,587 | 0.05% | 240,963 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $915,000 | 0.05% | 100,000 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $598,850 | 0.03% | 145,000 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $178,328 | 0.01% | 27,777 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $92,000 | 0.00% | 80,000 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $1,178 | 0.00% | 75,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.